coronaviru
diseas
caus
mainli
target
respiratori
system
howev
cardiac
arrhythmia
report
hospit
patient
patient
intens
care
unit
structur
andor
inflammatori
cardiac
damag
also
describ
heart
failur
episod
inhospit
patient
seri
time
write
sever
potenti
treatment
investig
candid
drug
may
caus
pr
prolong
eg
lopinavirritonavir
andor
qt
prolong
chloroquin
hydroxychloroquin
azithromycin
lopinavirritonavir
other
expectedli
short
treatment
durat
day
mitig
drug
cardiac
risk
extent
howev
individu
approach
weigh
risk
benefit
medic
affect
patient
import
indepth
discuss
multipl
candid
treatment
test
specif
cardiac
risk
beyond
scope
editori
like
quickli
becom
outdat
new
data
emerg
rather
aim
propos
pragmat
approach
mitig
potenti
risk
lethal
arrhythmia
use
drug
potenti
cardiac
effect
set
two
main
advers
event
report
databas
vigibas
world
health
organ
databas
individu
case
safeti
report
countri
faer
us
food
drug
administr
advers
event
report
system
number
sudden
cardiac
death
report
potenti
treatment
respect
hydroxychloroquin
lopinovirritonavir
imatinib
azithromycin
although
degre
underreport
advers
event
databas
like
worthwhil
note
hydroxychloroquin
azithromycin
instanc
prescrib
decad
hundr
million
patient
worldwid
recent
studi
raoult
et
al
potenti
benefit
combin
hydroxychloroquin
azithromycin
ecg
perform
initi
treatment
inpati
sever
symptom
includ
critic
care
hydroxychloroquineazithromycin
prolong
qtc
ms
develop
acut
renal
failur
strong
predictor
extrem
qtc
prolong
lethal
arrhythm
event
report
preliminari
seri
french
agenc
medic
safeti
ansm
report
case
event
possibl
relat
hydroxychloroquin
use
recommend
close
followup
possibl
advers
event
differ
drug
potenti
cardiac
effect
use
offlabel
covid
worth
note
medic
potenti
prolong
qt
interv
requir
ecg
prescrib
accord
label
nationwid
intern
level
occurr
qt
prolong
particularli
torsad
de
point
often
multifactori
risk
factor
divid
three
group
first
modifi
risk
factor
includ
use
drug
prolong
qt
interv
see
crediblemedsorg
serum
potassium
mmoll
bradycardia
bpm
hypocalcaemia
mgl
mmoll
hypomagnesemia
mgl
mmoll
second
nonmodifi
risk
factor
includ
inherit
long
qt
syndrom
femal
sex
age
year
intrins
baselin
qtc
ms
cardiac
diseas
acut
coronari
syndrom
heart
failur
episod
histori
kidney
liver
diseas
sepsi
third
one
could
anticip
risk
factor
attribut
myocard
arrhythmia
hypokalaemia
renal
failur
associ
risk
drug
toxic
allud
short
durat
treatment
day
associ
lower
risk
drug
accumul
arrhythmia
would
expect
longerterm
treatment
minim
risk
cardiac
event
patient
treat
drug
cardiac
effect
suggest
differ
workup
followup
depend
clinic
statu
biochem
paramet
potassium
creatinin
blood
level
minimum
diseas
sever
outpati
vs
inpati
fig
outpati
age
year
without
cardiac
hepat
digest
renal
comorbid
ecg
seem
mandatori
absenc
qtprolong
drug
howev
ecg
readili
perform
reason
j
u
r
n
l
p
r
e
p
r
f
initi
qtprolong
drug
defer
patient
serum
potassium
level
mmoll
correct
least
mmoll
qtprolong
drug
may
initi
patient
serum
potassium
level
mmoll
concurr
potassium
supplement
given
two
qtprolong
drug
initi
ecg
consid
mandatori
drug
administr
followup
depend
context
summar
figur
intens
care
ecg
systemat
well
close
perman
rhythm
monitor
focu
qtc
interv
remain
import
lower
qtc
limit
risk
consid
low
set
ms
repres
th
percentil
differ
normal
popul
studi
upper
limit
risk
appear
becom
high
set
ms
case
qtc
interv
ms
qtprolong
drug
prescrib
unless
deem
necessari
close
continu
rhythm
monitor
strategi
maintain
serum
potassium
mmoll
institut
qtprolong
drug
discontinu
scenario
well
baselin
qtc
interv
ms
repeat
ecg
perform
day
treatment
initi
ecg
perform
use
ambulatori
system
remot
monitor
capabl
allow
reliabl
qtc
measur
qtc
interv
prolong
ms
prolong
ms
rel
baselin
ventricular
arrhythmia
occur
treatment
qtprolong
drug
stop
deem
necessari
continu
qtprolong
medic
scenario
patient
hospit
close
monitor
advers
event
report
french
healthcar
author
http
signalementsocialsantegouvfrpsigihmutilisateursindexhtml
accueil
qtc
interv
difficult
measur
accur
wave
welldefin
autom
measur
provid
ecg
gener
reliabl
manual
measur
qtc
tangent
method
appropri
qt
interv
measur
lead
ii
correct
heart
rate
use
preced
rr
interv
per
bazett
fridericia
formula
heart
rate
bpm
http
wwwqtcalculatororg
case
pvc
ecg
mark
qtc
lengthen
follow
sinu
beat
may
marker
higher
risk
torsad
de
point
patient
qr
durat
ms
eg
bundl
branch
block
pace
ventricular
rhythm
modifi
approach
measur
adjust
qtc
need
propos
follow
formula
use
adjust
qtc
qtc
qr
durat
ms
threshold
ms
use
qtc
appli
adjust
qtc
doubt
difficult
case
advis
healthcar
provid
consid
seek
advic
colleagu
expertis
area
electrophysiologist
experi
care
patient
congenit
long
qt
syndrom
facilit
relev
centr
expertis
could
consid
establish
method
rapid
commun
matter
eg
dedic
email
address
could
central
nationalregion
registrywebsit
none
author
declar
conflict
interest
concern
articl
bpm
beat
per
min
ecg
electrocardiogram
egfr
estim
glomerular
filtrat
rate
k
potassium
pvc
prematur
ventricular
contract
